Citations (40)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Kimberly M. Thompson & Kamran Badizadegan. (2022) Health economic analyses of secondary vaccine effects: a systematic review and policy insights. Expert Review of Vaccines 21:3, pages 297-312.
Read now
Read now
Kimberly M. Thompson, Dominika A. Kalkowska & Kamran Badizadegan. (2021) Hypothetical emergence of poliovirus in 2020: part 2. exploration of the potential role of vaccines in control and eradication. Expert Review of Vaccines 20:4, pages 449-460.
Read now
Read now
Kimberly M. Thompson & Dominika A. Kalkowska. (2020) Review of poliovirus modeling performed from 2000 to 2019 to support global polio eradication. Expert Review of Vaccines 19:7, pages 661-686.
Read now
Read now
Kimberly M. Thompson & Dominika A. Kalkowska. (2019) Logistical challenges and assumptions for modeling the failure of global cessation of oral poliovirus vaccine (OPV). Expert Review of Vaccines 18:7, pages 725-736.
Read now
Read now
Radboud J. Duintjer Tebbens & Kimberly M. Thompson. (2018) Polio endgame risks and the possibility of restarting the use of oral poliovirus vaccine. Expert Review of Vaccines 17:8, pages 739-751.
Read now
Read now
Radboud J. Duintjer Tebbens & Kimberly M. Thompson. (2017) Poliovirus vaccination during the endgame: insights from integrated modeling. Expert Review of Vaccines 16:6, pages 577-586.
Read now
Read now
Malabi M Venkatesan & Lillian L Van de Verg. (2015) Combination vaccines against diarrheal diseases. Human Vaccines & Immunotherapeutics 11:6, pages 1434-1448.
Read now
Read now
Articles from other publishers (33)
Dominika A. Kalkowska, Steven G. F. Wassilak, Eric Wiesen, Cara C. Burns, Mark A. Pallansch, Kamran Badizadegan & Kimberly M. Thompson. (2023) Coordinated global cessation of oral poliovirus vaccine use: Options and potential consequences. Risk Analysis.
Crossref
Crossref
Dominika A Kalkowska, Steven GF Wassilak, Eric Wiesen, Concepcion F Estivariz, Cara C Burns, Kamran Badizadegan & Kimberly M Thompson. (2023) Complexity of options related to restarting oral poliovirus vaccine (OPV) in national immunization programs after OPV cessation. Gates Open Research 7, pages 55.
Crossref
Crossref
Emmanuel J. Vidor & John F. Modlin. 2023. Plotkin's Vaccines. Plotkin's Vaccines
890
913.e14
.
Yuyang Xu, Yan Liu, Jun Wang, Xinren Che, Jian Du, Xiaoping Zhang, Wenwen Gu, Xuechao Zhang & Wei Jiang. (2022) Cost-effectiveness of various immunization schedules with inactivated Sabin strain polio vaccine in Hangzhou, China. Frontiers in Public Health 10.
Crossref
Crossref
Yawen Jiang, Dan Cai & Si Shi. (2022) Economic evaluations of inactivated COVID-19 vaccines in six Western Pacific and South East Asian countries and regions: A modeling study. Infectious Disease Modelling 7:1, pages 109-121.
Crossref
Crossref
Kimberly M. Thompson. (2021) Modeling and Managing Poliovirus Risks: We are Where we are…. Risk Analysis 41:2, pages 223-228.
Crossref
Crossref
Kimberly M. Thompson & Dominika A. Kalkowska. (2020) Potential Future Use, Costs, and Value of Poliovirus Vaccines. Risk Analysis 41:2, pages 349-363.
Crossref
Crossref
Dominika A. Kalkowska & Kimberly M. Thompson. (2020) Modeling Undetected Live Poliovirus Circulation After Apparent Interruption of Transmission: Borno and Yobe in Northeast Nigeria. Risk Analysis 41:2, pages 303-311.
Crossref
Crossref
Kimberly M. Thompson & Dominika A. Kalkowska. (2020) Reflections on Modeling Poliovirus Transmission and the Polio Eradication Endgame. Risk Analysis 41:2, pages 229-247.
Crossref
Crossref
Dominika A. Kalkowska, Mark A. Pallansch, Steven G. F. Wassilak, Stephen L. Cochi & Kimberly M. Thompson. (2020) Global Transmission of Live Polioviruses: Updated Dynamic Modeling of the Polio Endgame. Risk Analysis 41:2, pages 248-265.
Crossref
Crossref
D. A. Kalkowska, M. A. Pallansch & K. M. Thompson. (2019) Updated modelling of the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus (iVDPV) excreters. Epidemiology and Infection 147.
Crossref
Crossref
Radboud J Duintjer Tebbens, Dominika A Kalkowsa & Kimberly M Thompson. (2018) Poliovirus containment risks and their management. Future Virology 13:9, pages 617-628.
Crossref
Crossref
Radboud J. Duintjer Tebbens, Mark A. Pallansch, Stephen L. Cochi, Derek T. Ehrhardt, Noha H. Farag, Stephen C. Hadler, Lee M. Hampton, Maureen Martinez, Steve G.F. Wassilak & Kimberly M. Thompson. (2018) Modeling Poliovirus Transmission in Pakistan and Afghanistan to Inform Vaccination Strategies in Undervaccinated Subpopulations. Risk Analysis 38:8, pages 1701-1717.
Crossref
Crossref
Emmanuel Vidor. 2018. Plotkin's Vaccines. Plotkin's Vaccines
841
865.e10
.
Radboud J. Duintjer Tebbens & Kimberly M. Thompson. (2018) Using integrated modeling to support the global eradication of vaccine-preventable diseases. System Dynamics Review 34:1-2, pages 78-120.
Crossref
Crossref
J.S. Koopman, C.J. Henry, J.H. Park, M.C. Eisenberg, E.L. Ionides & J.N. Eisenberg. (2017) Dynamics affecting the risk of silent circulation when oral polio vaccination is stopped. Epidemics 20, pages 21-36.
Crossref
Crossref
Kimberly M. Thompson & Radboud J. Duintjer Tebbens. (2017) Lessons From Globally Coordinated Cessation of Serotype 2 Oral Poliovirus Vaccine for the Remaining Serotypes. The Journal of Infectious Diseases 216:suppl_1, pages S168-S175.
Crossref
Crossref
Radboud J. Duintjer Tebbens & Kimberly M. Thompson. (2017) Costs and Benefits of Including Inactivated in Addition to Oral Poliovirus Vaccine in Outbreak Response After Cessation of Oral Poliovirus Vaccine Use. MDM Policy & Practice 2:1, pages 238146831769700.
Crossref
Crossref
R. J. DUINTJER TEBBENS & K. M. THOMPSON. (2016) Comprehensive screening for immunodeficiency-associated vaccine-derived poliovirus: an essential oral poliovirus vaccine cessation risk management strategy. Epidemiology and Infection 145:2, pages 217-226.
Crossref
Crossref
Radboud J Duintjer Tebbens & Kimberly M Thompson. (2016) The potential benefits of a new poliovirus vaccine for long-term poliovirus risk management. Future Microbiology 11:12, pages 1549-1561.
Crossref
Crossref
Kimberly M. Thompson & Radboud J. Duintjer Tebbens. (2016) Framework for Optimal Global Vaccine Stockpile Design for Vaccine-Preventable Diseases: Application to Measles and Cholera Vaccines as Contrasting Examples. Risk Analysis 36:7, pages 1487-1509.
Crossref
Crossref
Barbara P. Sanders, Isabel de los Rios Oakes, Vladimir van Hoek, Viki Bockstal, Tobias Kamphuis, Taco G. Uil, Yutong Song, Gillian Cooper, Laura E. Crawt, Javier Martín, Roland Zahn, John Lewis, Eckard Wimmer, Jerome H. H. V. Custers, Hanneke Schuitemaker, Jeronimo Cello & Diana Edo-Matas. (2016) Cold-Adapted Viral Attenuation (CAVA): Highly Temperature Sensitive Polioviruses as Novel Vaccine Strains for a Next Generation Inactivated Poliovirus Vaccine. PLOS Pathogens 12:3, pages e1005483.
Crossref
Crossref
Radboud J. Duintjer Tebbens, Mark A. Pallansch & Kimberly M. Thompson. (2015) Modeling the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus excretors and the potential benefits of antiviral drugs. BMC Infectious Diseases 15:1.
Crossref
Crossref
Kimberly M. Thompson & Radboud J. Duintjer Tebbens. (2015) Health and economic consequences of different options for timing the coordinated global cessation of the three oral poliovirus vaccine serotypes. BMC Infectious Diseases 15:1.
Crossref
Crossref
Radboud J. Duintjer Tebbens, Mark A. Pallansch, Stephen L. Cochi, Steven G.F. Wassilak & Kimberly M. Thompson. (2015) An economic analysis of poliovirus risk management policy options for 2013–2052. BMC Infectious Diseases 15:1.
Crossref
Crossref
Radboud J. Duintjer Tebbens, Mark A. Pallansch, Steven G. F. Wassilak, Stephen L. Cochi & Kimberly M. Thompson. (2015) Combinations of Quality and Frequency of Immunization Activities to Stop and Prevent Poliovirus Transmission in the High-Risk Area of Northwest Nigeria. PLOS ONE 10:6, pages e0130123.
Crossref
Crossref
Kimberly M. Thompson, Dominika A. Kalkowska & Radboud J. Duintjer Tebbens. (2015) Managing population immunity to reduce or eliminate the risks of circulation following the importation of polioviruses. Vaccine 33:13, pages 1568-1577.
Crossref
Crossref
Jean Guo, Sara Bolivar-Wagers, Nivedita Srinivas, Marisa Holubar & Yvonne Maldonado. (2015) Immunodeficiency-related vaccine-derived poliovirus (iVDPV) cases: A systematic review and implications for polio eradication. Vaccine 33:10, pages 1235-1242.
Crossref
Crossref
Kimberly M. Thompson & Radboud J. Duintjer Tebbens. (2014) Modeling the Dynamics of Oral Poliovirus Vaccine Cessation. The Journal of Infectious Diseases 210:suppl_1, pages S475-S484.
Crossref
Crossref
Dominika A. Kalkowska, Radboud J. Duintjer Tebbens & Kimberly M. Thompson. (2014) Modeling Strategies to Increase Population Immunity and Prevent Poliovirus Transmission in 2 High-Risk Areas in Northern India. The Journal of Infectious Diseases 210:suppl_1, pages S398-S411.
Crossref
Crossref
Radboud J. Duintjer Tebbens & Kimberly M. Thompson. (2014) Modeling the Potential Role of Inactivated Poliovirus Vaccine to Manage the Risks of Oral Poliovirus Vaccine Cessation. The Journal of Infectious Diseases 210:suppl_1, pages S485-S497.
Crossref
Crossref
Kimberly M Thompson. (2014) Polio endgame management: focusing on performance with or without inactivated poliovirus vaccine. The Lancet 384:9953, pages 1480-1482.
Crossref
Crossref
J. Reina. (2014) ¿Amenaza la poliomielitis a Europa?. Vacunas 15:3-4, pages 71-72.
Crossref
Crossref